Leader in precision medicine solutions and multispecialty clinic customer to discuss the promise of genetic data at the point of care
2bPrecise, a leader in precision medicine solutions, will present on the value of pharmacogenomics (PGx) at the AMIA 2021 Clinical Informatics Conference. The company will be joined by longtime customer Murfreesboro Medical Clinic and SurgiCenter (MMC) for the virtual presentation, "Quantitative and Qualitative Outcomes Using IT-Supported Pharmacogenomics at the Point of Care." Together, 2bPrecise and MMC will explore ways health IT tools and PGx testing can improve medication safety, reduce adverse drug events and accelerate therapeutic value for patients.
"Pharmacogenomics, or how drugs interact with a patient’s genes, is incredibly valuable when it comes to determining the best medication for a patient," said Dr. Joel Diamond, a practicing physician at Handelsman Family Practice in Pittsburgh, PA and chief medical officer at 2bPrecise. "Genetic profiles can eliminate trial-and-error prescribing by ensuring medications are safe and effective from the outset. As an organization on the forefront of precision medicine, we are thrilled to showcase at AMIA and share now MMC is leveraging our tools to better understand a patient’s genetic data and provide better care."
Dr. Diamond and MMC Chief Medical Informatics Officer and President Dr. Nicholas Cote will draw from their successful implementations of PGx programs to explore the role IT plays in giving providers better insight into patients’ genetic data to help inform clinical decisions. The duo will also discuss the obstacles commonly encountered when initiating point-of-care precision medicine programs, lessons learned and best practices from implementing these programs within their own practices, and measurable outcomes the organizations have experienced.
"Leveraging genetic data to identify how patients will metabolize certain medications is a critical step in ensuring patients receive high-value care," said Dr. Cote. "Powerful precision medicine solutions can give providers the necessary support to make care decisions with certainty. We look forward to presenting at AMIA and sharing our successes and real-world experiences with colleagues who might be considering similar programs."
Drs. Diamond and Cote’s session, "Quantitative and Qualitative Outcomes Using IT-Supported Pharmacogenomics at the Point of Care," will take place virtually Thursday, May 20, 2021 from 1:00–2:00 PM ET.
The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more. Learn more at www.2bPreciseHealth.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005164/en/
Aria Marketing (for 2bPrecise)